Our head of Business Development & Outsourcing, Samuel Mercer will be at #BIOEurope in Copenhagen Nov. 4-8. We will be exploring partnering opportunities for embodiments of our platform-based technology: lead product candidate, EP-104, a novel...
Eupraxia team presented results on our “Potential new treatment for knee osteoarthritis" in PAINWeek 2018 - Las Vegas
Our CEO, Dr. James Helliwell, CFO Alex Rothwell and Director of Outsourcing & BD, Sam Mercer will be at #BIO2018 Boston, June 4–7 @BIOConvention
Senior Director of Translational Science, Dr. Murray Webb will be in Chicago for the 6th Annual Drug Repositioning, Repurposing and Rescue Conference from June 27-28 2017
Our CEO, Dr. James Helliwell and Director of Outsourcing & BD, Sam Mercer will be at #BIO2017 San Diego, June 9–12 @BIOConvention
Sam Mercer, Head of Outsourcing and Business Development, will be attending the 89th Annual Western Veterinary Conference at the Mandalay Bay Convention Center in Las Vegas, March 5-9, 2017.
Vik Peck, Vice-President of Program Management will be presenting at the Pharma PPM Toolbox - the US edition of the world´s most popular pharmaceutical PPM conference - on February 9-10 in Jersey City, NJ. Vik will be presenting a Campfire Session entitled: "Big...
Meet Dr. James Helliwell, Eupraxia CEO and Sam Mercer, Director of Outsourcing and Business Development at the 35th Annual Healthcare Conference in SanFrancisco, January 9 - 12.
Eupraxia representatives will be at the 2016 AAPS annual meeting and expo, 13-17 Nov 2016, Denver, Colorado.
Eupraxia announces first patient dosed in phase I clinical trial of EP-104IAR to treat osteoarthritis-related pain
VICTORIA, BC – Eupraxia, an emerging pharmaceutical company focused on optimizing drug delivery, announced today the initiation of STEP UP – a phase I study of its lead investigational product (EP-104IAR), for the treatment of pain associated with osteoarthritis (OA)...